What is to-BBB technologies?
to-BBB technologies is a clinical-stage biotechnology firm dedicated to revolutionizing drug delivery across the blood-brain barrier. The company's proprietary G-Technology platform, which ingeniously combines pegylated liposomes with the endogenous tripeptide glutathione, aims to enhance the efficacy of existing drugs for severe conditions like brain cancer and neuroinflammatory diseases. By enabling drugs to reach the brain at systemically tolerable doses, to-BBB is paving the way for novel therapeutic interventions. The company is actively investigating the versatility of its platform with academic and pharmaceutical collaborators, with its lead internal product, 2B3-101, currently in a Phase I/IIa trial for brain tumors, and a second product, 2B3-201, slated for a Phase I study in neuroinflammatory diseases.
How much funding has to-BBB technologies raised?
to-BBB technologies has raised a total of $24.4M across 4 funding rounds:
Series A
$4.8M
Series B
$4.8M
Debt
$1.4M
Series C
$13.4M
Series A (2007): $4.8M with participation from Aescap
Series B (2011): $4.8M led by IBTM, Aescap, Jonghoud International, and Antea Participaties
Debt (2011): $1.4M, investors not publicly disclosed
Series C (2014): $13.4M featuring Antea, Jonghoud International, and Aescap Venture
Key Investors in to-BBB technologies
Antea Participaties
Antea Participaties is a Dutch investment company focused on the small and medium-sized enterprises (SMEs) sector, providing operational freedom and investing between 2 million and 7.5 million euros in companies with revenues between 7.5 million and 100 million euros, particularly in the Food, ICT/Media, and Business Services industries.
Jonghoud International
Jonghoud International participates in biotechnology, pharmaceutical laboratories, pharmacies, and ophthalmic centers, assisting with the purchase and sale of independent health care companies and strategic issues. The company was established in 2011 and is headquartered in HN Goes, Netherlands.
Aescap Venture
Aescap specializes in investing in innovative listed biotech companies with exceptional growth potential, focusing on those developing breakthrough treatments for diseases such as ALS, Alzheimer's, MS, and cancer. The company manages two funds and targets an average annual return of 20%.
What's next for to-BBB technologies?
The substantial enterprise-level funding received by to-BBB technologies positions it for accelerated development and potential commercialization of its innovative drug delivery platform. With ongoing clinical trials and strategic partnerships, the company is poised to address significant unmet needs in treating devastating brain disorders. The recent strategic investment signals strong confidence from backers in to-BBB's technology and its potential to transform patient outcomes, likely enabling the company to advance its pipeline, expand its research capabilities, and potentially scale its operations to meet future market demands.
See full to-BBB technologies company page
